Retrospective analysis shows MET overexpression correlates with improved progression-free survival in NSCLC, suggesting its role as a prognostic factor for immune checkpoint inhibitors.
Key Points
MET overexpression significantly improves progression-free survival in advanced non-small cell lung cancer patients.
78.9% of patients demonstrated MET overexpression, which correlates with positive immune checkpoint inhibitor response.
Assessment involved logistic regression and Kaplan–Meier analysis alongside Cox proportional hazards model for robust findings.
These findings highlight MET expression as a potential predictive biomarker for immunotherapy efficacy in NSCLC patients.